SFI
CTIC

Susquehanna Fundamental Investments’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Susquehanna Fundamental Investments’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-25,597
Closed -$82K – 1688
2020
Q4 		$82K Buy
+25,597
New +$85.1K ﹤0.01% 1435

Other funds holding CTIC

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Susquehanna Fundamental Investments's CTIC Position: Q1 2021 in Review

Susquehanna Fundamental Investments sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2021, closing a stake of 25,597 shares — an estimated $82K sold.

Susquehanna Fundamental Investments first reported a position in CTIC in Q4 2020 and held it in 1 quarter. The position peaked at $82K in Q4 2020. 55 funds tracked by Wall St. Rank hold CTIC as of Q1 2021.

  • Susquehanna Fundamental Investments reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 25,597 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2021, an estimated $82K.
  • Susquehanna Fundamental Investments first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2020 and held it in 1 quarter.
  • Susquehanna Fundamental Investments's CTI BioPharma Corp. (DE) Common Stock position peaked at $82K in Q4 2020.
  • 55 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2021, filed 17 May 2021.